Ray Dalio's BIO Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 10,632 shares of Bio-Rad Laboratories, Inc. (BIO) worth $2.98 M, representing 0.01% of the portfolio. First purchased in 2015-Q3, this long-term strategic position has been held for 41 quarters.
Based on 13F filings since 2013, Ray Dalio has maintained a long-term strategic position in BIO, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2017, adding 16,277 shares. Largest reduction occurred in Q4 2023, reducing 15,988 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Bio-Rad Laboratories (BIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bio-Rad Laboratories (BIO) Trades by Ray Dalio
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2015 | +2,978 | New Buy | 2,978 | $134.32 |
| Q4 2015 | -2,978 | Sold Out | 2,978 | $0.00 |
| Q4 2017 | +19,255 | New Buy | 19,255 | $238.69 |
| Q1 2018 | -15,646 | Reduce 81.26% | 3,609 | $250.21 |
| Q2 2018 | -1,777 | Reduce 49.24% | 1,832 | $288.76 |
| Q3 2018 | +184 | Add 10.04% | 2,016 | $313.00 |
| Q4 2018 | +4,574 | Add 226.88% | 6,590 | $232.17 |
| Q1 2019 | -6,590 | Sold Out | 6,590 | $0.00 |
| Q1 2022 | +385 | New Buy | 385 | $563.64 |
| Q2 2022 | +2,848 | Add 739.74% | 3,233 | $494.90 |
| Q3 2022 | +5,178 | Add 160.16% | 8,411 | $417.19 |
| Q4 2022 | +3,563 | Add 42.36% | 11,974 | $420.49 |
| Q1 2023 | -11,171 | Reduce 93.29% | 803 | $479.02 |
| Q2 2023 | +15,666 | Add 1950.93% | 16,469 | $379.12 |
| Q3 2023 | +290 | Add 1.76% | 16,759 | $358.45 |
| Q4 2023 | -15,988 | Reduce 95.40% | 771 | $322.89 |
| Q1 2024 | -771 | Sold Out | 771 | $0.00 |
| Q3 2025 | +10,632 | New Buy | 10,632 | $280.39 |
Ray Dalio's Bio-Rad Laboratories Investment FAQs
Ray Dalio first purchased Bio-Rad Laboratories, Inc. (BIO) in Q3 2015, acquiring 2,978 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Bio-Rad Laboratories, Inc. (BIO) for 41 quarters since Q3 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's largest addition to Bio-Rad Laboratories, Inc. (BIO) was in Q4 2017, adding 19,255 shares worth $4.6 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 10,632 shares of Bio-Rad Laboratories, Inc. (BIO), valued at approximately $2.98 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Bio-Rad Laboratories, Inc. (BIO) represents approximately 0.01% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's peak holding in Bio-Rad Laboratories, Inc. (BIO) was 19,255 shares, as reported at the end of Q4 2017. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.